Adding Decitabine & Venetoclax to RIC Pre-Allo SCT
A Phase I Trial to Evaluate the Safety and Efficacy of Addition of Novel Anti-leukemia Agents to Flu/Mel RIC Transplant for High-risk Myeloid Malignancies
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 20 patients (estimated)
- Sponsors
- University of Alabama at Birmingham
- Tags
- Hypomethylating Agents (HMA), BCL-2 Inhibitor, High Risk, Pre-Allogeneic Stem Cell Transplant
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2166
- NCT Identifier
- NCT07044544
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.